LCZ696B
Drug
Novartis Pharma AG
Total Payments
$478,293
Transactions
263
Doctors
56
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $241,204 | 174 | 34 |
| 2017 | $237,089 | 89 | 32 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $215,624 | 26 | 45.1% |
| Unspecified | $134,490 | 36 | 28.1% |
| Travel and Lodging | $121,549 | 119 | 25.4% |
| Food and Beverage | $6,631 | 82 | 1.4% |
Payments by Type
General
$343,803
227 transactions
Research
$134,490
36 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| CLCZ696B2320 | Novartis Pharma AG | $72,982 | 3 |
| CLCZ696B2319 | Novartis Pharma AG | $60,427 | 2 |
| CLCZ696B2314 | Novartis Pharma AG | $1,080 | 1 |
Top Doctors Receiving Payments for LCZ696B
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Boston, MA | $115,389 | 7 |
| , MD | Neurology | Sacramento, CA | $80,075 | 24 |
| , MD | Pediatrics | Philadelphia, PA | $64,380 | 25 |
| , MD | Cardiovascular Disease | Boston, MA | $32,815 | 18 |
| , MD | Cardiovascular Disease | Boston, MA | $27,534 | 13 |
| , MD | Internal Medicine | Boston, MA | $24,717 | 9 |
| , MD | Internal Medicine | Mpls, MN | $24,010 | 10 |
| , M.D | Pediatric Cardiology | Cincinnati, OH | $17,974 | 1 |
| , MD, MPH | Cardiovascular Disease | Stony Brook, NY | $16,428 | 4 |
| , MD | Neurology | Boston, MA | $10,605 | 4 |
| , MD | Advanced Heart Failure and Transplant Cardiology | Charleston, SC | $9,007 | 7 |
| , MD | Pediatric Cardiology | Bronx, NY | $8,137 | 3 |
| , MD | Pediatric Nephrology | Little Rock, AR | $8,100 | 4 |
| , MB | Nephrology | Minneapolis, MN | $5,670 | 3 |
| , MD | Emergency Medicine | Indianapolis, IN | $5,000 | 1 |
| , MD | Neurological Surgery | Chicago, IL | $2,558 | 2 |
| James Lewis | Gastroenterology | Washington, DC | $2,500 | 1 |
| , MD | Pediatrics | Saint Louis, MO | $2,255 | 4 |
| , MD | Family Medicine | Daytona Beach, FL | $2,202 | 6 |
| , MD | Cardiovascular Disease | Reno, NV | $1,425 | 6 |
| , MD | Internal Medicine | Topeka, KS | $1,257 | 6 |
| , MD | Cardiovascular Disease | Kingwood, TX | $1,236 | 6 |
| , M.D | Internal Medicine | Temple, TX | $1,207 | 6 |
| , M.D | Pediatric Cardiology | Philadelphia, PA | $1,180 | 3 |
| , MD | Interventional Cardiology | Sacramento, CA | $1,175 | 8 |
Ad
Manufacturing Companies
- Novartis Pharma AG $478,293
Product Information
- Type Drug
- Total Payments $478,293
- Total Doctors 56
- Transactions 263
About LCZ696B
LCZ696B is a drug associated with $478,293 in payments to 56 healthcare providers, recorded across 263 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharma AG.
Payment data is available from 2017 to 2018. In 2018, $241,204 was paid across 174 transactions to 34 doctors.
The most common payment nature for LCZ696B is "Consulting Fee" ($215,624, 45.1% of total).
LCZ696B is associated with 3 research studies, including "CLCZ696B2320" ($72,982).